60 Investor presentation First nine months of 2023 Patient access to anti-obesity me the US and IO The ~50 million people having access to Wegovy® demonstrates the recognition of Obesity as a chronic disease ~110m Obesity prevalence in US adults 1 ~60m Commercial Channel • >80% formulary access • >50% of employers opt-in ~38m People with commercial coverage ~12m Medicaid 2 1 Prevalence: Adult obesity facts. Centers for Disease Control and Prevention, https://www.cdc.gov/obesity/data/adult.html; US Cens 2 Also includes DoD and government employees Note: Obesity is defined as BMI > 30
Download PDF file